HUMA - Humacyte, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

HUMA

HUMACYTE, INC.

NASDAQ

$0.65

▼ DOWN 6.15% (-0.04)

KEY STATISTICS

Market Cap$109.22 M

52w High$2.55

52w Low$0.53

Dividend Yield—

Frequency—

P/E-1.08

Volume4.92M

Shares Out.168.00M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Laura E. Niklason

COMPENSATION 2026

Salary$633,606

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$14,594

Total$5,234,908

ABOUT

SECTOR

Healthcare

WENT PUBLIC

December 1, 2020

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

184

PRICE TARGET

Target High$2.00

Target Low$2.00

Target Median$2.00

Target Consensus$2.00

UPCOMING EARNINGS

DateNov 11, 2026

DayWednesday

Rev. Est.$769.38K

NOV

WED

PRICE

$0.65 ▼ DOWN 6.15% (−$0.04)

About Humacyte, Inc.

https://www.humacyte.com ↗

Humacyte, Inc. develops off-the-shelf, bioengineered human tissues, including acellular vessels for vascular repair, reconstruction, and various medical applications, aiming to improve treatment options across multiple therapeutic areas.

INDUSTRY

Biotechnology

A PRODUCT HUMACYTE, INC. IS KNOWN FOR

Symvess™ (acellular tissue engineered vessel-tyod)

Symvess™ is an FDA-approved, bioengineered human acellular vessel launched in 2025, providing a universal, off-the-shelf vascular conduit for urgent extremity arterial revascularization when autologous veins are unavailable.

COMPETITORS

COMPETITOR

Revenue by Products

PRODUCT	Q3-2021	Q1-2025	Q2-2025	Q1-2026
Product	—	$147K	$100K ▼	$493K ▲
Reimbursement of certain allowable costs related to grants	$200K	—	—	—
Product and Service Other	—	$370K	$201K ▼	$2K ▼